Acthar Gel in Participants With Pulmonary Sarcoidosis
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if Acthar Gel is safe and effective to treat
pulmonary sarcoidosis.
Participants will be randomly assigned (like flipping a coin) to receive a shot under their
skin of Acthar Gel or a matching placebo gel that has no drug in it. They will receive their
assigned shot twice a week for 24 weeks.
All participants who complete the 24-week treatment period will be eligible to receive Acthar
Gel for 24 more weeks, even if they were originally in the placebo group.